Merge Hemo (Model RCSV2 (v11.3))
Merge Healthcare Incorporated · Decision date Nov 5, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-11-05 for Merge Hemo, Model RCSV2 (v11.3), submitted by Merge Healthcare Incorporated of Hartland, Wisconsin, under 510(k) number K262171. The application was received on 06/26/2026 and reviewed as a Traditional 510(k) by the Cardiovascular panel; it was not reviewed by a third party, is not a combination product, and no Predetermined Change Control Plan was authorized. SESE in this pathway denotes clearance rather than PMA approval.
The device falls under regulation 870.1425 with classification product code DQK and the classification name Computer, Diagnostic, Programmable, in the Cardiovascular specialty. The source page does not describe the specific components, software changes or performance data supporting the clearance, and no decision statement or summary is included, so the technical basis for the SESE finding remains unknown from this record.
The page was last updated 11/09/2026. Any cleared labeling, indications or limitations should be confirmed against the FDA decision documents rather than inferred from this database entry.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 5, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262171
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Merge Healthcare Incorporated
- Product code
- DQK
- Decision code
- SESE
- Decision date
- Nov 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Computer, Diagnostic, Programmable.
- Applicant
- Merge Healthcare Incorporated
- Product code
- DQK
- FDA device class
- 2
FDA decision timeline
K262171 received
Application receipt date recorded by FDA.
K262171 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DQK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VIVO (9002)K261886 | Catheter Precision, Inc. | 510(k) clearance | Oct 30, 2026 | FDA |
PulseAPI SmartWatchK254226 | PulseAI, Ltd. | 510(k) clearance | Oct 27, 2026 | FDA |
STAR Apollo Mapping SystemK263380 | Rhythm AI, Ltd. | 510(k) clearance | Oct 23, 2026 | FDA |
| Centerline Biomedical | 510(k) clearance | Oct 1, 2026 | FDA | |
S-Patch CardioAIK254255 | Wellysis Corp. | 510(k) clearance | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merge Healthcare Incorporated
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Hartland, WI
Sources and methodology
- Original FDA record: K262171
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


